DexCom
DXCM
798 hedge funds and large institutions have $27.6B invested in DexCom in 2022 Q2 according to their latest regulatory filings, with 85 funds opening new positions, 314 increasing their positions, 302 reducing their positions, and 137 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 314 | Existing positions reduced: 302
7% less funds holding
Funds holding: 862 → 798 (-64)
20% less call options, than puts
Call options by funds: $282M | Put options by funds: $352M
38% less first-time investments, than exits
New positions opened: 85 | Existing positions closed: 137
43% less capital invested
Capital invested by funds: $48.3B → $27.6B (-$20.7B)
47% less funds holding in top 10
Funds holding in top 10: 17 → 9 (-8)
294.53% less ownership
Funds ownership: 388.89% → 94.36% (-295%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$166M |
| 2 |
Morgan Stanley
New York
|
+$145M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$123M |
| 4 |
Sands Capital Management
Arlington,
Virginia
|
+$105M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$88.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$437M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$263M |
| 3 |
Jennison Associates
New York
|
-$168M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$135M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$119M |
DXCM Hedge Fund Activity: Q2 2022 in Review
798 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q2 2022, worth a combined $27.6B — down 43% from $48.3B a quarter earlier.
Sellers outnumbered buyers: 137 funds closed out of DXCM and 85 opened new positions — a net loss of 52 holders — while 302 trimmed existing stakes and 314 added.
The largest buyer was Citadel Advisors, adding an estimated $166M. The largest seller was Fidelity Investments, cutting an estimated $437M.
- 798 institutional investors held DexCom (DXCM) as of Q2 2022, down from 862 in Q1 2022.
- Funds reported $27.6B of DexCom stock for Q2 2022, down 43% quarter-over-quarter.
- 85 funds opened new DexCom positions in Q2 2022 and 137 closed out, a net change of -52 holders.
- The largest DexCom buyer in Q2 2022 was Citadel Advisors, an estimated $166M added.
- The largest DexCom seller in Q2 2022 was Fidelity Investments, an estimated $437M sold.
Based on aggregated 13F filings for Q2 2022.